Hokkaido University Hospital

Site:	Hokkaido University Hospital
Address:
City:	Sapporo
State:	Hokkaido
Zip:	060-8648
Country:	Japan

Phase	Trial	Trial Status	Site Status	Drug [desc]	NCT#
3	Study of Regorafenib as a 3rd-line or Greater Treatment for Gastrointestinal Stromal Tumors (GIST) (GRID)	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506)	NCT01271712
1	A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)	Active, not recruiting	Closed	Pimitespib + Imatinib	NCT05245968
3	Phase III, Open-Label Study of Nilotinib Versus Imatinib in GIST Patients (ENESTg1)	Completed	Closed	Nilotinib or Imatinib	NCT00785785
2	Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib	Completed	Closed	Nilotinib	NCT00718562
3	A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy (StrateGIST 3)	Recruiting	Active	IDRX-42	NCT07218926
2	Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)	Recruiting	Active, not recruiting	Belzutifan	NCT04924075